Several DRI peptides have been evaluated as anti-tumor drug candidates in preclinical studies, e.g., DRI peptide RE-A7R targeting VEGFR2 [46], FOXO4-DRI peptide targeting p53:FOXO4 interaction [47], or in clinical trials, e.g., AM111 targeting JNK:c-Jun interaction [48]. The gene discussed is TP53; the disease is neoplasm.